Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?
The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Optimal First-Line Treatment for Metastatic ALK+ NSCLC Optimal First-Line Treatment for Metastatic ALK+ NSCLC
When it comes to first-line treatment options for metastatic ALK+ non-small cell lung cancer, what is the optimal choice?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
Roche presents positive phase Ib data at AACR 2023, reinforcing the potential of its KRAS G12C inhibitor divarasib in advanced solid tumours
In the phaseIb GO42144 study,divarasib in combination withcetuximab, an anti-EGFR therapy, led to a confirmed overall response in 62% of people with advanced colorectal cancerThe treatment combination demonstrated a manageable safety profileThe data presented at AACR 2023further support Roche ' s programme to developdivarasib as single-agent or in combination for treating solid tumoursBasel, 18 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from the phase Ib GO42144 study, which show that treatment with the KRAS G12C inhibitor, divarasib (GDC-6036), in combination with anti-EGFR therapy, ...
Source: Roche Investor Update - April 18, 2023 Category: Pharmaceuticals Source Type: news
'Potential' New Option for Operable NSCLC
(MedPage Today) -- ORLANDO -- The addition of durvalumab (Imfinzi) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-L1 inhibitor alone could become a new standard option for resectable non-small cell lung cancer (NSCLC)... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 17, 2023 Category: Hematology Source Type: news
AACR: AstraZeneca's Imfinzi lung cancer data raise new questions
AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable non-small cell lung cancer. | AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable…#astrazeneca #pd1 (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
CT body composition assessment helps determine lung cancer prognosis
Assessing lung cancer sufferers' body composition with CT imaging can help clinician...Read more on AuntMinnie.comRelated Reading:
CT shows link between sarcopenia, depression in lung cancer patients
Radiomics, AI can guide NSCLC treatment decisions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 14, 2023 Category: Radiology Source Type: news
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients
The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC). Called the Pragmatica-Lung Study (or S2302), this is one…#nih #nsclc #nci #fda #monicambertagnolli #cancermoonshot #elilillyandcompany #keytruda #merck #jameshdoroshow (Source: Reuters: Health)
Source: Reuters: Health - April 13, 2023 Category: Consumer Health News Source Type: news
CT body composition measures help predict lung cancer recurrence
Body composition measurements from preoperative CT images can help determin...Read more on AuntMinnie.comRelated Reading:
AI denoising reduces LDCT lung cancer screening exam radiation dose
PET AI model improves lung cancer staging
PET/CT radiomics could help select patients for immunotherapy
CT shows link between sarcopenia, depression in lung cancer patients
CT radiomics predicts survival in NSCLC patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 12, 2023 Category: Radiology Source Type: news
Timing of RT With Immunotherapy in Metastatic NSCLC Timing of RT With Immunotherapy in Metastatic NSCLC
Radiotherapy followed by immunotherapy within 1 –12 months ― but not sooner or later ― may boost progression-free survival in patients with metastatic non–small cell lung cancer, suggests new study.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Immune Checkpoint Inhibitor Efficacy in BRAF-Mutant NSCLC Immune Checkpoint Inhibitor Efficacy in BRAF-Mutant NSCLC
Various immune checkpoint inhibitors are used in the treatment of non-small cell lung cancer, but how effective are they in patients with BRAF mutations?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Cullinan: Trading Way Below Cash
Cullinan Oncology (NASDAQ:CGEM) is a cancer focused drug developer with a mid stage pipeline. Their approach is to develop differentiated molecules with first-in-class potential, and one of the ways they approach this is to test their molecules as monotherapies in early stages in order to “avoid…#cullinanoncology #cgem #cullinan #egfr #egfrex20ins #nsclc #taihopharmaceuticals #taiho #rp2d #fda (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2023 Category: Consumer Health News Source Type: news
FDA accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Source: World Pharma News)
Source: World Pharma News - April 5, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
